Free tool
FAERS Monitor: Ztlido
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207962 or its brand name (Ztlido, Lidocaine). Reports on generic versions are filed under their own applications.
Reports
49,881
Serious
36,261
73% of reports
Hospitalization
17,871
Death reported
5,056
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,715
- pain3,226
- fatigue3,117
- nausea3,103
- headache2,866
- off label use2,726
- dyspnoea2,224
- pneumonia2,056
- diarrhoea2,017
- sinusitis1,952
- vomiting1,889
- product dose omission issue1,772
- fall1,745
- dizziness1,743
- death1,713
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 281 |
| 2005 | 257 |
| 2006 | 318 |
| 2007 | 314 |
| 2008 | 376 |
| 2009 | 451 |
| 2010 | 531 |
| 2011 | 1,089 |
| 2012 | 1,215 |
| 2013 | 757 |
| 2014 | 1,133 |
| 2015 | 1,871 |
| 2016 | 3,208 |
| 2017 | 2,539 |
| 2018 | 3,298 |
| 2019 | 4,174 |
| 2020 | 5,431 |
| 2021 | 3,793 |
| 2022 | 3,546 |
| 2023 | 3,900 |
| 2024 | 4,006 |
| 2025 | 4,135 |
| 2026 | 3,254 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,278 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sinusitisSignal | 1,952 | 8.2 | 7.8 | 12,096 |
| pneumoniaSignal | 2,056 | 2.7 | 2.6 | 2,198 |
| product dose omission issueSignal | 1,772 | 2.6 | 2.4 | 1,682 |
| painSignal | 3,226 | 2.2 | 2.1 | 2,217 |
| fallSignal | 1,745 | 2.2 | 2.1 | 1,177 |
| headache | 2,866 | 1.9 | 1.9 | 1,321 |
| vomiting | 1,889 | 1.7 | 1.6 | 550 |
| fatigue | 3,117 | 1.7 | 1.6 | 909 |
| dyspnoea | 2,224 | 1.7 | 1.6 | 596 |
| nausea | 3,103 | 1.7 | 1.6 | 833 |
| dizziness | 1,743 | 1.5 | 1.4 | 272 |
| diarrhoea | 2,017 | 1.3 | 1.3 | 159 |
| off label use | 2,726 | 1.3 | 1.3 | 212 |
| drug ineffective | 3,715 | 1.2 | 1.2 | 119 |
| death | 1,713 | 0.8 | 0.8 | 56 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.